| Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention … F Franchi, F Rollini, A Rivas, M Wali, M Briceno, M Agarwal, Z Shaikh, ... Circulation 139 (14), 1661-1670, 2019 | 133 | 2019 |
| Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study F Franchi, F Rollini, J Rivas Rios, A Rivas, M Agarwal, M Kureti, ... Circulation 137 (23), 2450-2462, 2018 | 57 | 2018 |
| Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention LH Cavallari, F Franchi, F Rollini, L Been, A Rivas, M Agarwal, DM Smith, ... Journal of translational medicine 16, 1-10, 2018 | 46 | 2018 |
| Cangrelor versus ticagrelor in patients treated with primary percutaneous coronary intervention: impact on platelet activity, myocardial microvascular function and infarct size … S Ubaid, TJ Ford, C Berry, HM Murray, B Wrigley, N Khan, MR Thomas, ... Thrombosis and Haemostasis 119 (07), 1171-1181, 2019 | 41 | 2019 |
| Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes: results of a randomized pharmacodynamic study in a feasibility investigation of rapid genetic … F Franchi, F Rollini, J Rivas, A Rivas, M Agarwal, M Briceno, M Wali, ... Basic to Translational Science 5 (5), 419-428, 2020 | 26 | 2020 |
| Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results … F Franchi, F Rollini, E Garcia, JR Rios, A Rivas, M Agarwal, M Kureti, ... Thrombosis and Haemostasis 120 (01), 083-093, 2020 | 25 | 2020 |
| Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study F Franchi, DM Yaranov, F Rollini, A Rivas, JR Rios, L Been, Y Tani, ... BMJ Open Diabetes Research and Care 9 (1), e001939, 2021 | 24 | 2021 |
| Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results … F Franchi, F Rollini, G Faz, JR Rivas, A Rivas, M Agarwal, M Briceno, ... Journal of the American Heart Association 9 (8), e015865, 2020 | 24 | 2020 |
| Pharmacodynamic effects of vorapaxar in patients with and without diabetes mellitus: results of the OPTIMUS-5 study F Franchi, F Rollini, V Kairouz, J Rivas Rios, A Rivas, M Agarwal, ... JACC: Basic to Translational Science 4 (7), 763-775, 2019 | 21 | 2019 |
| Cangrelor in patients with coronary artery disease pretreated with ticagrelor: the switching antiplatelet (SWAP)-5 study F Franchi, L Ortega-Paz, F Rollini, M Galli, L Been, G Ghanem, ... Cardiovascular Interventions 16 (1), 36-46, 2023 | 17 | 2023 |
| Pharmacodynamic and pharmacokinetic effects of a low maintenance dose ticagrelor regimen versus standard dose clopidogrel in diabetes mellitus patients without previous major … F Franchi, F Rollini, L Been, M Briceno, N Maaliki, M Wali, A Rivas, ... Circulation 142 (15), 1500-1502, 2020 | 13 | 2020 |
| Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet … M Galli, F Franchi, F Rollini, L Been, PA Jaoude, A Rivas, X Zhou, S Jia, ... European Heart Journal-Cardiovascular Pharmacotherapy 8 (7), 728-737, 2022 | 8 | 2022 |
| Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease M Galli, F Franchi, F Rollini, L Been, P Abou Jaoude, A Rivas, X Zhou, ... Thrombosis and Haemostasis 122 (08), 1341-1351, 2022 | 8 | 2022 |
| Prevalencia de síndrome metabólico en el Sector Olivett: El Junquito L De Oliveria, E García, J Torres, A Rivas Rev Venez Endocrinol Metab 4 (3), 16-42, 2006 | 8 | 2006 |
| Loading with oral P2Y12 receptor inhibitors: to crush or not to crush? D Alexopoulos, S Dragasis, N Kafkas Thrombosis and Haemostasis 119 (07), 1037-1047, 2019 | 6 | 2019 |
| Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti-Platelet … L Ortega-Paz, F Franchi, F Rollini, M Galli, L Been, G Ghanem, ... Thrombosis and Haemostasis 124 (03), 263-273, 2024 | 4 | 2024 |
| Switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the switching antiplatelet-6 (SWAP-6) study F Franchi, F Rollini, L Ortega-Paz, L Been, S Giordano, M Galli, ... Cardiovascular Interventions 16 (20), 2528-2539, 2023 | 4 | 2023 |
| Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study. F Franchi, L Ortega-Paz, F Rollini, L Been, A Rivas, N Maaliki, X Zhou, ... Eurointervention: Journal of Europcr in Collaboration with the Working Group …, 2023 | 4 | 2023 |
| Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease F Franchi, F Rollini, L Been, N Maaliki, P Abou Jaoude, A Rivas, X Zhou, ... European Heart Journal-Cardiovascular Pharmacotherapy 8 (5), 452-461, 2022 | 4 | 2022 |
| Impact of timing of pharmacodynamic assessment on platelet reactivity in patients treated with cangrelor F Franchi, F Rollini, M Galli, L Been, G Ghanem, A Shalhoub, A Rivas, ... Cardiovascular Interventions 14 (21), 2410-2412, 2021 | 3 | 2021 |
